Xencor, Inc., of Monrovia, has received "a broad patent covering optimized monoclonal antibody variants and their application for extending in vivo half-life of antibodies." Opinion: I suppose those who need to know understand what that means, but I
think it means Xencor has figured out a way to keep antibodies alive and working in people's bodies for longer.
http://goo.gl/vueIE
- Brad Haugaard
No comments:
Post a Comment